Laxasan (Sodium Picosulfate)

Laxasan (sodium picosulfate) is a stimulant laxative that acts on the large intestine to promote bowel movements in several clinical situations.

• Constipation: Provides rapid colonic stimulation to facilitate stool passage in patients with functional constipation.
• Bowel preparation before colonoscopy: Produces thorough evacuation of the colon, allowing clear visualization of the mucosa during colonoscopic examination.
• Bowel preparation before other diagnostic procedures: Enables effective cleansing of the bowel prior to radiologic or endoscopic investigations such as sigmoidoscopy or CT colonography.

• Sodium picosulfate is a pro‑drug that is converted by colonic bacteria into the active metabolite, a diphenylmethane derivative. The metabolite stimulates the enteric nervous system, increasing peristaltic activity and promoting secretion of water and electrolytes into the intestinal lumen, which together accelerate transit and facilitate evacuation of fecal material. The effect is localized to the colon, resulting in minimal systemic absorption and a favorable safety profile when used as directed.

Sodium picosulfate may cause a range of gastrointestinal and systemic reactions, which are categorized by frequency and severity.

Common Side Effects

• Abdominal cramps: Cramping sensation in the lower abdomen during bowel evacuation.
• Diarrhea: Loose, watery stools occurring shortly after dosing.
• Nausea: Mild queasiness that may accompany the laxative effect.
• Flatulence: Increased intestinal gas production.
• Urgency: Sudden need to defecate.
• Mild electrolyte imbalance: Small changes in serum sodium or potassium levels.

Serious or Rare Side Effects

• Severe dehydration: Marked loss of body fluids requiring medical attention.
• Electrolyte disturbances: Significant hypo‑ or hyper‑natremia or potassium shifts.
• Allergic reaction: Rash, itching, swelling, or anaphylaxis.
• Colitis: Inflammation of the colon presenting with pain and fever.
• Rectal bleeding: Visible blood in stool indicating mucosal injury.

When prescribing or dispensing Laxasan, several safety considerations should be observed to minimize risk.

• Assess renal function: Evaluate kidney status before use, especially in patients with chronic kidney disease.
• Monitor electrolyte balance: Check serum sodium and potassium levels if prolonged or high‑dose therapy is anticipated.
• Avoid use in intestinal obstruction: Do not administer when mechanical blockage of the bowel is present.
• Use with caution in the elderly: Older adults may be more sensitive to fluid loss and electrolyte shifts.
• Do not exceed recommended dose: Follow the prescriber’s instructions and avoid repeated dosing without medical guidance.
• Store at ambient temperature: Keep the product in its original packaging, protect from moisture and direct sunlight.

Sodium picosulfate can interact with other medicines, altering its efficacy or increasing the risk of adverse events.

Major Interactions (Avoid)

• Opioid analgesics: Counteract the laxative effect, potentially leading to severe constipation.
• Other stimulant laxatives: Combined use may cause excessive bowel stimulation and electrolyte loss.
• Anticholinergic agents: Reduce colonic motility, diminishing the intended therapeutic outcome.

Moderate Interactions (Monitor Closely)

• Antacids: May affect the conversion of the pro‑drug, requiring dose adjustment.
• Diuretics: Concomitant use can exacerbate fluid and electrolyte depletion.
• Antihypertensive drugs: Potential for enhanced hypotensive effect due to volume loss.
• NSAIDs: Increased risk of gastrointestinal irritation when both agents are used.